MASH (metabolic dysfunction-associated steatohepatitis, the renamed NASH) is the liver disease that has emerged as the next major peptide drug indication after obesity. Both GLP-1s and dual/triple agonists have shown MASH benefit, with the mechanism question — direct hepatic effect versus weight-loss-mediated — only recently resolved.
The most cited 2026 read: a Cell Metabolism paper from Sinai Health pinned semaglutide's MASH reversal to liver sinusoidal endothelial cells (LSECs), which account for ~3% of liver cell volume but drive hepatoprotection. Mice without LSEC GLP-1 receptors saw no liver improvement despite 20% weight loss; mice without brain appetite receptors still reversed MASH. That decouples MASH benefit from weight loss for the first time.
Regulatory milestones followed. The FDA approved semaglutide for MASH with fibrosis in August 2025. On June 19, 2026, Japan's MHLW granted Novo Nordisk a partial change approval making Wegovy the first approved MASH treatment in Japan (without cirrhosis, moderate-to-advanced fibrosis), co-promoted with Sumitomo Pharma. The approval rests on ESSENCE Phase 3 Part 1 data showing semaglutide 2.4 mg superior to placebo on both liver fibrosis improvement and MASH resolution. Boehringer Ingelheim's survodutide full 48-week Phase 2 NEJM data (47-62% MASH improvement without fibrosis worsening) and Altimmune's pemvidutide 48-week IMPACT data at EASL 2026 added the GLP-1/glucagon dimension; the survodutide SYNCHRONIZE-1 Phase 3 readout is expected late 2026.
Stories here cover trial readouts, regulatory approvals, mechanism papers, and the broader liver-disease pipeline. See #liver-disease, #liver, #essence-phase-3, and #survodutide for adjacent threads.
Madrigal Pharmaceuticals announced May 20 that multiple abstracts from its Rezdiffra (resmetirom) development and real-world evidence programs will be presented at EASL 2026 in Barcelona. Headline analyses include cardiovascular risk markers — secondary analysis of Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 examining improvements in Lp(a), LDL-C, and ApoB — and portal hypertension risk improvement in compensated MASH cirrhosis (F4c) measured by ANTICIPATE-NASH risk scores. Real-world evidence and noninvasive biomarker analyses round out the slate. Rezdiffra (a thyroid hormone receptor β agonist, not a peptide) was approved March 2024 as the first FDA-approved MASH therapy for noncirrhotic MASH with F2-F3 fibrosis. The EASL data extend the case toward compensated MASH cirrhosis and cardiovascular outcomes — a competitive context for the GLP-1/glucagon peptide programs (semaglutide ESSENCE, pemvidutide IMPACT, survodutide SYNCHRONIZE-1, retatrutide MASLD Phase 3) running on parallel tracks.
The European Association for the Study of the Liver (EASL) Congress 2026 runs May 27-30 in Barcelona. Novo Nordisk said it will present ESSENCE trial analyses of semaglutide in MASH, including a liver safety analysis led by Philip Newsome, an analysis in menopausal women led by Mazen Abdelmalek, and a Japanese subgroup analysis led by Atsushi Nakajima, building on the August 2025 FDA approval of semaglutide for MASH with fibrosis. Elsewhere in the field, Lilly's Phase 3 SYNERGY-Outcomes trial (NCT07165028) is enrolling about 4,500 people with MASLD to test tirzepatide and retatrutide against placebo on serious liver outcomes, and Boehringer Ingelheim's survodutide is in the Phase 3 LIVERAGE and LIVERAGE-Cirrhosis MASH trials.
Eight days ahead of EASL Congress 2026 in Barcelona (May 27-30), Novo Nordisk released new analyses from the Phase 3 ESSENCE program showing semaglutide 2.4 mg holds a favorable hepatic safety profile across MASH subgroups, including the first dedicated Japanese MASH cohort and a women-in-menopause subset. Gastrointestinal events remained the leading adverse-event signal, with small discontinuation rates. MASH affects an estimated 250 million people globally with roughly 9 in 10 cases undiagnosed; the trial data reinforce the FDA's August 2025 MASH-with-fibrosis approval and broaden the prescribing case ahead of the EASL plenaries.
In a 98-person substudy of the Phase 2 retatrutide obesity trial, published in Nature Medicine in 2024, liver fat fell 86.0% from baseline at 48 weeks on 12 mg versus 4.6% on placebo, and 93% of people on that dose with week-48 scans reached normal liver fat (below 5%); fewer than half of participants had week-48 MRIs. Lilly's Phase 3 SYNERGY-Outcomes trial (NCT07165028), which began in October 2025, is enrolling about 4,500 adults with MASLD at higher risk of serious liver outcomes to test retatrutide and tirzepatide against placebo, with time to the first major adverse liver outcome as its main endpoint.
Following the April 28 SYNCHRONIZE-1 obesity topline (16.6% weight loss at 76 weeks), Boehringer Ingelheim and Zealand Pharma confirmed that survodutide — their dual GLP-1/glucagon agonist — has two global Phase 3 MASH trials underway: LIVERAGE in adults with MASH and fibrosis stages F2 or F3, and LIVERAGE-Cirrhosis in compensated MASH cirrhosis. The Phase 3 program follows Phase 2 data showing 83% of MASH patients achieved histological improvement at 48 weeks. The MASH track positions survodutide alongside tirzepatide's SYNERGY-NASH and broader Lilly Phase 3 activity in the metabolic-liver-disease space, with full SYNCHRONIZE-1 data slated for ADA 2026 in June.
Researchers at Toronto's Sinai Health published in Cell Metabolism that semaglutide acts directly on liver sinusoidal endothelial cells (LSECs) to reverse MASH independently of weight loss. Although LSECs account for only ~3% of liver cell volume, they are the key driver of hepatoprotection. Semaglutide reversed MASH in mice lacking brain appetite receptors, while mice lacking LSEC receptors saw no liver improvement despite losing 20% body weight.
GLP-1 RAs, particularly semaglutide, are showing robust clinical data for liver disease with significant rates of disease resolution and improvement in liver fibrosis.
The FDA granted breakthrough therapy designation to survodutide, a dual glucagon/GLP-1 receptor agonist by Boehringer Ingelheim, for treating adults with MASH.